Cytosine arabinoside deamination in human leukaemic myeloblasts and resistance to cytosine arabinoside therapy. 1981

A L Harris, and D G Grahame-Smith, and C G Potter, and C Bunch

1. The conversion of cytosine arabinoside into its active metabolite cytosine arabinoside triphosphate, and catabolism by deamination to uracil arabinoside, was measured in intact marrow myeloblasts from patients with acute myeloid leukaemia. The ratio of uracil arabinoside/cytosine arabinoside triphosphate ranged from 0.32 to 19.11. 2. The effect of tetrahydrouridine, and inhibitor of cytosine arabinoside deamination, on cytosine arabinoside triphosphate production was studied. The greatest increase of cytosine arabinoside triphosphate production caused by addition of tetrahydrouridine was 27%. 3. The increase in cytosine arabinoside triphosphate production wad not related to the ratio of uracil arabinoside/cytosine arabinoside triphosphate or to the deaminase activity per 10(6) cells. It wa proportional to the percentage change of cytosine arabinoside in the incubation medium. 4. The sensitivity of DNA synthesis to inhibition by cytosine arabinoside was measured in myeloblasts from 11 patients. Addition of tetrahydrouridine did not increase the sensitivity of the marrow to cytosine arabinoside. 5. Cytosine arabinoside deamination is unlikely to be an important mechanism of resistance in myeloblasts in vivo, although it may produce apparent resistance in vitro.

UI MeSH Term Description Entries
D001853 Bone Marrow The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells. Marrow,Red Marrow,Yellow Marrow,Marrow, Bone,Marrow, Red,Marrow, Yellow
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D003561 Cytarabine A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) Ara-C,Arabinofuranosylcytosine,Arabinosylcytosine,Cytosine Arabinoside,Aracytidine,Aracytine,Cytarabine Hydrochloride,Cytonal,Cytosar,Cytosar-U,beta-Ara C,Ara C,Arabinoside, Cytosine,Cytosar U,beta Ara C
D003641 Deamination The removal of an amino group (NH2) from a chemical compound. Deaminations
D004273 DNA, Neoplasm DNA present in neoplastic tissue. Neoplasm DNA
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004351 Drug Resistance Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration. Resistance, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001085 Arabinofuranosylcytosine Triphosphate A triphosphate nucleotide analog which is the biologically active form of CYTARABINE. It inhibits nuclear DNA synthesis. Ara-CTP,Arabinosylcytosine Triphosphate,Cytarabine Triphosphate,Cytosine Arabinoside Triphosphate,Ara CTP,Triphosphate, Arabinofuranosylcytosine,Triphosphate, Arabinosylcytosine,Triphosphate, Cytarabine,Triphosphate, Cytosine Arabinoside

Related Publications

A L Harris, and D G Grahame-Smith, and C G Potter, and C Bunch
February 1976, British journal of haematology,
A L Harris, and D G Grahame-Smith, and C G Potter, and C Bunch
January 1973, Scandinavian journal of haematology,
A L Harris, and D G Grahame-Smith, and C G Potter, and C Bunch
April 1979, British journal of clinical pharmacology,
A L Harris, and D G Grahame-Smith, and C G Potter, and C Bunch
August 1983, European journal of cancer & clinical oncology,
A L Harris, and D G Grahame-Smith, and C G Potter, and C Bunch
January 1979, Leukemia research,
A L Harris, and D G Grahame-Smith, and C G Potter, and C Bunch
January 1973, Acta haematologica,
A L Harris, and D G Grahame-Smith, and C G Potter, and C Bunch
May 1983, British journal of cancer,
A L Harris, and D G Grahame-Smith, and C G Potter, and C Bunch
June 1975, International journal of cancer,
A L Harris, and D G Grahame-Smith, and C G Potter, and C Bunch
October 1977, Cancer treatment reports,
Copied contents to your clipboard!